5909 Sea Otter Pl
47 articles with Synteract Inc.
Syneos Health announced on Wednesday that it has agreed to acquire Synteract, a full-service Contract Research Organization (CRO) focused on the biopharmaceutical industry.
Given the enhanced strategic solutions that often result from the intersecting expertise of Synteract’s centers of development, clients will derive further benefit from the therapeutic knowledge and clinical development acumen gained from these key additions.
Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, congratulates its Vice President, Rare and Orphan Diseases, Lisa Dilworth, for being named to the 2019 PharmaVOICE 100.
Synteract Bolsters Its Oncology, Neuro Degenerative and Rare Disease Centers of Development with Two New Executives
Christopher Heckman to focus on Oncology Center of Development as Dr. Art Wamil joins as lead neurologist
Synteract Acquires Pediatric CRO KinderPharm to Further Strengthen its Pediatric Center of Development
KinderPharm provides advanced pharmacometric modeling and clinical trial simulation technologies coupled with juvenile formulation and toxicology services.
Synteract’s Francoise Desir Named to the PharmaVOICE 100 — The Most Inspiring People in Life Sciences
Respected team leader and motivator recognized for her passion and dedication in bringing clinical trials to life
Synteract, an innovative contract research organization (CRO) providing full-service, Phase I-IV services enabling biopharma companies to bring new medicines to market, has added Cheryl Murphy as senior vice president, Clinical Development to its executive team.
CRO with three decades in advancing innovative therapies will highlight new focus areas at annual Drug Information Association event
Synteract Repositions Itself with Centers of Therapeutic Development and Unveils Updated Brand Platform
Contract research organization, with three decades of experience in advancing innovative therapies to market, tightens its focus while increasing investment in market positioning
He joins Synteract from Chiltern, a Covance company, where he was vice president, Global Business Development Biopharma.
Deonanan joins Synteract from IQVIA (formerly Quintiles) where he was CFO of the organization’s Research and Development Solutions segment.
Synteract, Inc. (San Diego) and Harrison Clinical Research GmBHh Close Deal to Form Multinational CRO
Synteract, Inc. (San Diego) Appoints Keith Kelson as Chief Financial Officer and Member of Executive Council and Philip Doren, Ph.D., as Vice President, Biometrics
Synteract, Inc. (San Diego) Participating in January Pharmaceutical Industry Events on the West Coast
Gryphon-Owned Synteract, Inc. (San Diego) Agrees to Acquire Multinational CRO Harrison Clinical Research GmBH
Synteract, Inc. (San Diego) Upgrades Safety Database Systems to Oracle Argus to Increase Efficiencies
Synteract, Inc. (San Diego) Leadership to Provide Insights at Industry Events on Both West and East Coasts
Synteract, Inc. (San Diego) and Rempex Pharmaceuticals Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure